Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

NCT02680951 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawn due to lack of participants.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Dasatinib
DRUG: Fludarabine
DRUG: Cytarabine
DRUG: Idarubicin
DRUG: Intrathecal (IT) cytarabine

Sponsor

Emory University